GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well. Pulmonary fibrosis is a lung disease characterized by widespread scarring, primarily caused by immune cells called macrophages. Then, they used experiments on mice to confirm the connections among diabetes, SARS-CoV-2 infection and the onset of pulmonary fibrosis. Treated mice showed reduced pulmonary fibrosis compared to those not treated with GLP-1 agonists, suggesting that the drug could lessen the risk of fibrous buildup. Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes.